How to Discuss Healthcare Trends: The Informed View Framework

Introduction

"What healthcare trends are you following?" tests a different competency than the deal question. The deal question tests analytical depth on a specific transaction. The trend question tests whether you can connect macro-level industry dynamics to micro-level banking implications. Interviewers want to see that you understand how structural forces (regulatory changes, technology shifts, demographic trends) translate into M&A advisory opportunities, valuation impacts, and client conversations. A strong trend answer is not an industry overview. It is a banking-relevant analysis that demonstrates you think about healthcare through a deal-making lens.

Part 1: What Is Happening

Start with a factual description of the trend, anchored in specific data points. Vague statements ("GLP-1 drugs are getting popular") signal surface-level preparation. Specific data ("the GLP-1 market reached approximately $63-70 billion in 2025 and is projected to reach $130-200 billion by 2030") signals genuine engagement.

Part 2: Why It Matters for Banking

This is the critical bridge that most candidates miss. Every trend you discuss should connect directly to banking activity. Ask yourself: does this trend create M&A opportunities? Does it change how we value companies? Does it affect deal structures or client advisory conversations? If you cannot answer at least one of these questions, the trend is not worth discussing in an interview.

Part 3: Your Analytical Take

Analytical Take

A specific, defensible perspective on a healthcare trend that goes beyond describing what is happening to argue what it means. An analytical take should be (1) specific enough to disagree with (not "GLP-1 is important" but "GLP-1 will create more losers than winners among healthcare services companies"), (2) grounded in evidence (supported by data or logical reasoning, not speculation), and (3) connected to banking (the implication should be relevant to M&A, valuation, or advisory). The analytical take is what transforms a trend summary into a demonstration of independent thinking.

Example 1: The GLP-1 Revolution

Example 2: The Patent Cliff Supercycle

What is happening: "Approximately **$236 billion** in branded drug revenue is losing patent protection by 2030. This is the largest patent cliff in biopharma history, concentrated in a few years among the industry's most profitable products."

Why it matters for banking: "The cliff is the primary structural driver of the biopharma M&A supercycle. 2025 produced approximately $228 billion in announced biotech deal value. Every major pharma company is in acquisition mode because internal R&D cannot replace revenue on the required timeline. For bankers, this creates unprecedented deal flow in both sell-side (advising clinical-stage biotechs being acquired) and buy-side (advising pharma companies on target evaluation and pipeline valuation)."

Your analytical take: "I think asset scarcity is the underappreciated dynamic. Each mega-deal removes a target from the available universe. Companies that delay acquisition risk a depleted target landscape at higher prices. This scarcity premium should accelerate deal activity in 2026-2027, not slow it down."

Example 3: AI in Healthcare

Example 4: The IRA and Portfolio Reshaping

What is happening: "The IRA's Medicare price negotiation took effect in January 2026, with first-round discounts of 38-79% on 10 drugs. The pill penalty (7-year vs. 13-year negotiation eligibility) has reduced small molecule R&D investment by approximately 70%."

Why it matters for banking: "The IRA is shifting pharma M&A strategy toward biologics and orphan drugs, which have longer protection from negotiation. This changes the relative valuation of acquisition targets: biologic pipeline assets command premiums that did not exist pre-IRA. For bankers modeling pharma SOTP valuations, the IRA requires explicit negotiation-driven revenue step-downs."

Your analytical take: "I think the EPIC Act, which would equalize the negotiation timeline, has a meaningful probability of passing. If it does, it would partially reverse the small molecule devaluation and create upward valuation adjustments for oral drug pipeline assets. This is a policy catalyst that could shift M&A dynamics."

The next article covers behavioral interview questions specific to healthcare IB, where smaller team dynamics and scientific content create unique behavioral demands.